Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
NAPANEE, Ontario, March 16, 2018 -- ABcann Global Corporation (TSXV:ABCN) (Frankfurt:23Q) (OTC:ABCCF) ("ABcann" or the "Company") announced that Ken Clement, ABcann's founder and director, has resigned from the Board of Directors.
Paul Lucas, ABcann's Chair, commented, "On behalf of the Board, we thank Ken for his vision in starting the company and growing it from a start-up organization into a well-funded publicly-traded licensed producer with a bright future. We wish Ken well in his future endeavours."
About ABcann:
ABcann holds production and sales licenses from Health Canada. Its flagship facility in Napanee, Ontario contains proprietary plant-growing technology, centred on its specially designed, environmentally-controlled growing chambers. This approach results in the production of pharmaceutical-grade cannabis products.
The Company is expanding its cultivation capacity and pursuing partnerships and product development opportunities domestically, as well as in select international markets, such as Germany, Australia and Israel.
ON BEHALF OF THE BOARD OF DIRECTORS
"Barry Fishman"
Barry Fishman
CEO and Director
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact: Barry Fishman (CEO and Director) [email protected] Michael Bumby (CFO) [email protected]
